Loading...

World-Class Retina Care. Community-Based Caring.

Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD

Posted On October 28, 2024 / By / Posted in Uncategorized

Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD

Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of

read more
Posted On August 21, 2024 / By / Posted in Blog

Texas Retina Honors Founder Dr. Vaiser with Donation to Retina Foundation

On behalf of the entire Texas Retina team, Gary Edd Fish, MD, recently presented a $2,000 donation to the Retina Foundation to honor the 90th birthday of one of Texas Retina’s founders,

read more
Posted On August 15, 2024 / By / Posted in Blog

Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease

Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for

read more
Posted On July 25, 2024 / By / Posted in Blog

Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting

Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual

read more
Posted On July 24, 2024 / By / Posted in Blog

Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting

Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the

read more
Posted On May 9, 2024 / By / Posted in Blog

Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology

At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand

read more
Posted On February 23, 2024 / By / Posted in Blog

Texas Retina Recognizes Laurie Griffis for 35 Years of Service

Since Texas Retina was founded more than 50 years ago, our physicians and leadership have fostered a family environment. As a result, we are fortunate to have numerous team members who have

read more
Posted On January 31, 2024 / By / Posted in Blog

New Clinical Trials Available at Texas Retina

At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one

read more
Posted On November 14, 2023 / By / Posted in Blog

Celebrating Our Visionary Founders

Many of our “founding physicians” met for dinner this past weekend, including Albert Vaiser, MD, and William Hutton, MD, who along with William Snyder, MD, established Texas Retina Associates more than 50 years

read more
Posted On October 11, 2023 / By / Posted in Blog

Dr. Abbey Publishes Case Report on Macular Hole Closure with Intravitreal Dexamethasone Implant

In the September 2023 issue of the peer-reviewed medical journal Ophthalmic Surgery, Lasers and Imaging Retina, Texas Retina’s Ashkan Abbey, MD, describes the use of a dexamethasone intravitreal implant to close a

read more